Treating Blood Cancers

Chelsey Winegar, LCSW, MBA, Intermountain Health, Murray, UT

Recorded on January 8, 2026

Chelsey Winegar, LCSW, MBA

Manager of Oncology Services

Intermountain Health

Murray, UT

Join Chelsey Winegar, LCSW and Manager of Oncology Services at Intermountain Health in Murray, UT, as she breaks down the key differences between burnout and compassion fatigue, and why understanding both is essential for the well being of healthcare professionals and the patients they serve.
Chelsey shares practical strategies for recognizing early warning signs, monitoring staff wellness, and building supportive, stigma free environments. The episode also highlights resources and education to help clinicians maintain resilience in demanding clinical settings. Listen in to learn more today!

Mentioned on this episode:

Trauma Stewardship

Additional Blood Cancer United Resources:

Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education

Blood Cancer United Resources for Patients

Lore Gruenbaum, PhD, Blood Cancer United, Washington, DC

Recorded on December 18, 2025

Lore Gruenbaum, PhD

Chief Scientific Officer & Senior Vice President of Research

Blood Cancer United

Washington, DC

Join Dr. Lore Gruenbaum, Chief Scientific Officer and Senior Vice President of Research at Blood Cancer United, to provide practice-changing data in hematologic malignancies from the 67th American Society of Hematology (ASH) Annual Meeting. Explored are breakthroughs in multiple myeloma, AML, CLL, and advances in cell therapy. Discussion also covers the growing use of artificial intelligence to accelerate precision medicine, spotlighting the Blood Cancer United Beat AML® Master Clinical Trial as a model for AI-driven trial design and real-time clinical decision-making. Tune in today for the key takeaways you need to know!

Additional Blood Cancer United Resources:

Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education

Blood Cancer United Resources for Patients

Raymond Mailhot, MD, MPH, University of Miami, Miami, FL

Recorded on December 2, 2025

Raymond Mailhot, MD, MPH

Department of Radiation Oncology

University of Miami

Miami, FL

Join us with Dr. Raymond Mailhot from the University of Miami as we explore how social determinants of health shape patient experiences, treatment decisions, and outcomes. He discusses the importance of cultural competence in delivering equitable, patient-centered care and shares practical communication strategies to better engage patients and collaborate effectively. This episode offers actionable insights to strengthen relationships and improve overall care quality. Tune in today to gain practical strategies that will enhance your approach to patient-centered care and drive better outcomes!

Additional Blood Cancer United Resources:

Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education

Blood Cancer United Medical Debt Case Management Program for Patients

Blood Cancer United Additional Resources for Patients

Paul J. Hampel, MD, Mayo Clinic, Rochester, MN

Recorded on November 4, 2025

Paul J. Hampel, MD

Assistant Professor of Medicine

Division of Hematology, Department of Medicine

Mayo Clinic

Rochester, MN

In this episode, Dr. Paul Hampel from Mayo Clinic Rochester takes a comprehensive look at hairy cell leukemia (HCL). He reviews the current diagnostic work-up, including immunophenotypic and molecular testing, and highlights key clinical features that distinguish HCL from related disorders. Dr. Hampel also discusses approved frontline therapies and evidence-based approaches for relapsed or refractory disease, with attention to infection risk and supportive care. The conversation explores emerging agents, novel combinations, and clinical trials shaping the next wave of HCL management. Join us for this expert discussion, offering practical insights to enhance care and outcomes for patients with HCL.

Michael J. Mauro, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Recorded on October 23, 2025

Michael J. Mauro, MD

Director, Chronic Myeloid Leukemia Program

Professor of Medicine, Leukemia Service

Memorial Sloan Kettering Cancer Center

New York, NY

Tune in for this expert-led discussion with Dr. Michael Mauro from Memorial Sloan Kettering Cancer Center on the evolving management of chronic myeloid leukemia (CML) in the era of tyrosine kinase inhibitors (TKIs) and newly approved FDA therapies. Dr. Mauro explores how TKIs have transformed prognosis, key factors guiding initial therapy selection, and best practices for managing treatment-related side effects. He also shares updates on TKI discontinuation criteria, long-term monitoring, and a forward look at ongoing trials and emerging therapeutic advances shaping the future of CML care. Gain actionable insights to enhance patient outcomes today!